Tirzepatide in UK Digital Practice: Real-World Weight Loss at Scale
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Rosenior-Patten O, Lees Z, Rowe R, et al.
Aug 6, 2026 · Published in: Diabetes, Obesity and Metabolism
Digital prescribing supports significant weight loss with tirzepatide.
THC:CBD Extract Modestly Eases Subjective MS Spasticity
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Liang D, Weir DL, Thevasahayam S, et al.
Aug 4, 2026 · Published in: British Journal of Clinical Pharmacology
Also in Medication Safety
Antidiabetic drug safety profiles expand significantly post-marketing.
Dapagliflozin plus pioglitazone improves glycemia and hepatic steatosis markers
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Joshi S, Samajdar SS, Gupta A, et al.
Aug 4, 2026 · Published in: Frontiers in Clinical Diabetes and Healthcare
Also in Gastroenterology / Hepatology
Improved glycemic and liver outcomes found with combination therapy in T2DM.
Oral Orforglipron Added to Titrated Glargine Lowers HbA1c Without More Hypoglycemia
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Giorgino F, D'Souza S, Ludwig L, et al.
Aug 4, 2026 · Published in: JAMA
ACHIEVE-5 gives pharmacists the first randomized data on an oral nonpeptide glucagon-like peptide 1 (GLP-1) receptor agonist layered onto titrated basal insulin in type 2 diabetes.
From Glucose-Centric to Outcomes-Driven: ADA 2026 Reshapes Diabetes Therapy
Reference Card Endocrinology / Diabetes / Obesity
Aug 2, 2026 · Published in: PharmD Signal Reference Card
How GLP-1 RAs and SGLT2 inhibitors displaced metformin as the default first-line in type 2 diabetes management.
GLP-1 Agonists Linked to Lower Antidepressant and Addiction Drug Starts
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Alfonso Arvez MJ, Wade S, Goordeen D, et al.
Jul 31, 2026 · Published in: Clinical Pharmacology and Therapeutics
Also in Psychiatry / Psychopharmacology
GLP-1RAs linked to reduced need for antidepressants and addiction medications.
Network Meta-Analysis Ranks Diabetes Drugs by Cardiovascular Benefit
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Silverii GA, Velardi V, Marinelli C, et al.
Jul 30, 2026 · Published in: Diabetes, Obesity & Metabolism
Also in Cardiology
Diabetes drugs SGLT2i, GLP1RA, and tirzepatide cut cardiovascular events and mortality.
Perioperative Dapagliflozin Halves Postoperative AKI After Cardiac Surgery
Analysis Nephrology / Renal Pharmacy Hypothesis-generating Grade: Moderate
Oosterom-Eijmael MJP, Hulst AH, de Oliveira NPM, et al.
Jul 30, 2026 · Published in: JAMA
Also in Perioperative / Anesthesia, Endocrinology / Diabetes / Obesity
Dapagliflozin cuts acute kidney injury risk post-cardiac surgery.
Oral Semaglutide Cuts Heavy Drinking but Misses Craving Endpoint
Analysis Behavioral Health / Addiction Medicine Hypothesis-generating Grade: Low
Schacht JP, Sakai JT, Raymond K, et al.
Jul 29, 2026 · Published in: The American Journal of Psychiatry
Also in Endocrinology / Diabetes / Obesity
Semaglutide potentially reduces heavy drinking in alcohol use disorder.
Balanced Crystalloids No Faster Than Saline for DKA Resolution
Analysis Critical Care / ICU Confirmatory Grade: Low
Soliman KAR, Hassan Ali AO, Ameer F, et al.
Jul 28, 2026 · Published in: Journal of Critical Care Medicine (Universitatea De Medicina Si Farmacie Din Targu-Mures)
Also in Endocrinology / Diabetes / Obesity
No clear winner between balanced crystalloids and saline in DKA resuscitation.
Emerging Anti-Obesity Targets Extend Beyond Incretin Pharmacotherapy
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Very Low
Lee S, Song H, Kwon Y
Jul 28, 2026 · Published in: Pharmaceuticals (Basel, Switzerland)
Innovative anti-obesity drugs offer hope beyond current treatments.
Empagliflozin Modestly Improves Liver Enzymes in MASLD, Not Lipids
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Karimi M, Tahmasebi A, Ramezanipour S, et al.
Jul 27, 2026 · Published in: Endocrinology, Diabetes & Metabolism
Also in Gastroenterology / Hepatology
Empagliflozin reduces liver enzymes in MASLD patients, showing promise.
Complementary SGLT2 Inhibitor Plus GLP-1 Agonist Therapy in Type 2 Diabetes
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Porterfield LR, Nadeem S, Swanson D, et al.
Jul 18, 2026 · Published in: Current Atherosclerosis Reports
Combining SGLT2is and GLP-1RAs may revolutionize diabetes management.
IDegLira Outperforms Glargine in One-Week Intensive Diabetes Therapy
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Sun Y, Li X, Xu L
Jul 13, 2026 · Published in: Endocrine
IDegLira outperforms insulin glargine for short-term diabetes control.
Combining SGLT2 Inhibitors and GLP-1 Agonists: Heart Failure Signal, Uncertain Evidence
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Very Low
Chuang MH, Ho CW, Wang HY, et al.
Jul 12, 2026 · Published in: CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
Combining the two classes lowered heart failure admissions but not MACE or major kidney events.